TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
2.300
+0.050 (2.22%)
At close: Mar 9, 2026, 4:00 PM EDT
2.264
-0.036 (-1.56%)
After-hours: Mar 9, 2026, 7:52 PM EDT
TherapeuticsMD Revenue
TherapeuticsMD had revenue of $784.00K in the quarter ending September 30, 2025, with 43.33% growth. This brings the company's revenue in the last twelve months to $2.80M, up 75.19% year-over-year. In the year 2024, TherapeuticsMD had annual revenue of $1.76M with 35.25% growth.
Revenue (ttm)
$2.80M
Revenue Growth
+75.19%
P/S Ratio
9.52
Revenue / Employee
$2,796,000
Employees
1
Market Cap
26.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.76M | 459.00K | 35.25% |
| Dec 31, 2023 | 1.30M | -68.66M | -98.14% |
| Dec 31, 2022 | 69.96M | 67.39M | 2,619.12% |
| Dec 31, 2021 | 2.57M | -62.30M | -96.03% |
| Dec 31, 2020 | 64.87M | 15.23M | 30.67% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 75.58M |
| InterCure | 72.16M |
| Aytu BioPharma | 62.64M |
| Cumberland Pharmaceuticals | 41.28M |
| Zhengye Biotechnology Holding | 21.46M |
| SCYNEXIS | 20.60M |
| BioXcel Therapeutics | 752.00K |
| Talphera | 28.00K |
TXMD News
- 4 months ago - TherapeuticsMD Announces Third Quarter 2025 Financial Results - Business Wire
- 7 months ago - TherapeuticsMD Announces Second Quarter 2025 Financial Results - Business Wire
- 10 months ago - TherapeuticsMD Announces First Quarter 2025 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces Full Year 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces Third Quarter 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying - Benzinga
- 1 year ago - TherapeuticsMD Announces Second Quarter 2024 Financial Results - Business Wire
- 1 year ago - TherapeuticsMD Announces First Quarter 2024 Financial Results - Business Wire